A Myostatin Pathway Inhibitor In Combination With A Glp-1 Pathway Activator For Use In Treating Metabolic Disorders
Patent No. EP4358995 (titled "A Myostatin Pathway Inhibitor In Combination With A Glp-1 Pathway Activator For Use In Treating Metabolic Disorders") was filed by Scholar Rock on Jun 22, 2022. The application was issued on Dec 3, 2025.
Patent Summary
A myostatin-selective inhibitor is used to treat metabolic disorders—including type 2 diabetes mellitus (T2D), obesity, obesity associated with T2D, or metabolic syndrome—in conjunction with a GLP-1 analog. The inhibitor is a myostatin-selective antibody or antigen-binding fragment that binds myostatin with no detectable binding or potency toward GDF11 or Activin A. The GLP-1 analog binds and activates the GLP-1 receptor and comprises the amino acid sequence EGTFTSD (SEQ ID NO: 116) and/or HXXGXFTXD (SEQ ID NO: 117), where X is any amino acid residue. Both agents are administered in amounts sufficient to treat the disorder, aiming for weight management and improved body composition, specifically enhancing lean mass relative to fat mass.
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4358995
- Application Number
- EP22744054A
- Filing Date
- Jun 22, 2022
- Status
- Granted And Under Opposition
- Oct 31, 2025
- Publication Date
- Dec 3, 2025
- External Links
- Slate, Register , Google Patents